Voxelotor
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Voxelotor: From Sickle Cell Disease to Hereditary Thrombocytopenia with Normal Platelets
One-Sentence Summary
Voxelotor is a hemoglobin oxygen-affinity modulator known for its clinical use in sickle cell disease (this original indication is not confirmed by structured registry data in this pack — see note below — but is described in the accompanying mechanistic rationale). The TxGNN model predicts potential efficacy for Hereditary Thrombocytopenia with Normal Platelets, with a very high prediction score (99.58%) but currently zero supporting clinical trials and zero publications. The evidence pack’s own analysis flags this prediction as a likely knowledge-graph clustering artifact rather than a genuine pharmacological signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Sickle cell disease (inferred from MOA description in the evidence rationale; not confirmed by structured regulatory data — see Data Gap DG002) |
| Predicted New Indication | Hereditary thrombocytopenia with normal platelets |
| TxGNN Prediction Score | 99.58% |
| Evidence Level | L5 (model prediction only, no clinical trials or literature) |
| Denmark Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for voxelotor is formally flagged as a Data Gap (DG002, High severity) in this evidence pack — no verified DrugBank/SmPC MOA record was retrieved. However, the rationale text accompanying the TxGNN predictions consistently describes voxelotor as a hemoglobin oxygen-affinity modulator that inhibits polymerization of sickle hemoglobin (HbS), which is the mechanism underlying its known clinical use in sickle cell disease. This description should be treated as background context only, not as verified structured data, until confirmed via a proper DrugBank/regulatory query.
The predicted new indication — hereditary thrombocytopenia with normal platelets — is a rare inherited platelet-function disorder. Its underlying biology involves megakaryocyte development and platelet signaling pathways, which is mechanistically distinct from voxelotor’s red-blood-cell-targeted, hemoglobin-polymerization mechanism. The evidence pack’s own repurposing rationale explicitly states there is no direct biological connection between the two conditions.
Notably, four of the five distinct diseases among the top-10 TxGNN predictions for voxelotor are platelet-related or thrombocytopenia conditions, all scoring within a narrow band (0.9951–0.9958). The evidence pack’s authors interpret this as a possible knowledge-graph embedding cluster effect rather than a drug-specific signal. A further confound is noted: patients with sickle cell disease often present with coexisting platelet-count abnormalities (e.g., due to splenic dysfunction), which may have caused the model to learn a comorbidity association rather than a true treatment relationship. In the complete absence of clinical trial or literature support, this prediction should be treated as hypothesis-generating only.
Clinical Trial Evidence
Currently no related clinical trials registered (ClinicalTrials.gov and ICTRP searches for voxelotor against this indication both returned zero results).
Literature Evidence
Currently no related literature available (PubMed search for voxelotor against this indication returned zero results).
Denmark Market Information
Voxelotor’s Denmark market status is recorded as Not marketed, with 0 registered marketing authorisations in the dataset. No product name, dosage form, or approved indication information is therefore available.
Safety Considerations
Please refer to the approved Summary of Product Characteristics (SmPC) for safety information. (Key warnings, contraindications, and drug-drug interaction data are all marked as Data Gaps in this evidence pack; the TFDA/regulatory label information required for a full safety assessment — Data Gap DG001, Blocking severity — has not yet been obtained.)
Conclusion and Next Steps
Decision: Hold
Rationale: This is an L5, model-prediction-only signal with no supporting clinical trials, no supporting literature, and no confirmed mechanistic link — the evidence pack’s own analysis suggests the score may reflect a knowledge-graph clustering artifact among platelet-disorder nodes rather than a genuine drug-disease relationship. Voxelotor is also not marketed in Denmark, and a Blocking-level safety data gap prevents any preliminary safety assessment.
To proceed, the following is needed:
- Regulatory label / SmPC safety data (warnings, contraindications, DDI) — currently Blocking Data Gap (DG001)
- Verified mechanism-of-action data from DrugBank — currently High-severity Data Gap (DG002)
- Independent confirmation that the TxGNN score is not an artifact of embedding-space clustering among platelet-disorder nodes
- Preclinical or mechanistic studies specifically evaluating any link between hemoglobin-polymerization modulation and platelet-disorder pathophysiology, before any further clinical evaluation is considered
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.